LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Search

Twist Bioscience Corp

Geschlossen

BrancheGesundheitswesen

26.84 -10.41

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

23.18

Max

29.97

Schlüsselkennzahlen

By Trading Economics

Einkommen

60M

20M

Verkäufe

3.3M

96M

Gewinnspanne

21.227

Angestellte

923

EBITDA

22M

-24M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+31.16% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

14. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

59M

1.9B

Vorheriger Eröffnungskurs

37.25

Vorheriger Schlusskurs

26.84

Nachrichtenstimmung

By Acuity

50%

50%

171 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Twist Bioscience Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Nov. 2025, 21:34 UTC

Ergebnisse

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

13. Nov. 2025, 23:45 UTC

Market Talk

Nikkei May Fall After Wall Street's Weakness -- Market Talk

13. Nov. 2025, 23:42 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

13. Nov. 2025, 23:41 UTC

Market Talk

Gold Edges Higher on Possible Dip-Buying -- Market Talk

13. Nov. 2025, 23:24 UTC

Ergebnisse

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

13. Nov. 2025, 23:24 UTC

Ergebnisse

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

13. Nov. 2025, 23:23 UTC

Ergebnisse

JBS NV 3Q EPS 52c >JBS

13. Nov. 2025, 23:23 UTC

Ergebnisse

JBS NV 3Q Sales $22.6B >JBS

13. Nov. 2025, 23:04 UTC

Market Talk

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

13. Nov. 2025, 22:02 UTC

Ergebnisse

Nu Holdings 3Q Net $783M >NU

13. Nov. 2025, 22:01 UTC

Ergebnisse

Nu Holdings 3Q Rev $4.2B >NU

13. Nov. 2025, 21:51 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

13. Nov. 2025, 21:50 UTC

Ergebnisse

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

13. Nov. 2025, 21:45 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

13. Nov. 2025, 21:41 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

13. Nov. 2025, 21:36 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

13. Nov. 2025, 21:36 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

13. Nov. 2025, 21:36 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

13. Nov. 2025, 21:36 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

13. Nov. 2025, 21:36 UTC

Akquisitionen, Fusionen, Übernahmen

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

13. Nov. 2025, 21:33 UTC

Market Talk

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

13. Nov. 2025, 21:33 UTC

Ergebnisse

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

13. Nov. 2025, 21:31 UTC

Ergebnisse

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

13. Nov. 2025, 21:25 UTC

Ergebnisse

Figure Tech Solutions 3Q Rev $156.4M >FIGR

13. Nov. 2025, 21:25 UTC

Ergebnisse

Figure Tech Solutions 3Q EPS 34c >FIGR

13. Nov. 2025, 21:23 UTC

Ergebnisse

Intchains Group 3Q Rev $1.3M >ICG

13. Nov. 2025, 21:03 UTC

Ergebnisse

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

13. Nov. 2025, 21:02 UTC

Ergebnisse

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

13. Nov. 2025, 21:01 UTC

Ergebnisse

Applied Materials 4Q Rev $6.8B >AMAT

13. Nov. 2025, 21:01 UTC

Ergebnisse

Applied Materials 4Q Gross Margin 48.0% >AMAT

Peer-Vergleich

Kursveränderung

Twist Bioscience Corp Prognose

Kursziel

By TipRanks

31.16% Vorteil

12-Monats-Prognose

Durchschnitt 41.8 USD  31.16%

Hoch 50 USD

Tief 36 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Twist Bioscience Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

5 ratings

5

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

31.56 / 38.6884Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

171 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat